Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration
New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.
New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.
comments(0)
5-min edit window · permanent after that